Navigation Links
Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Date:7/28/2008

rements for skin care and supplements in Japan."

About Toyo Bio-Pharma

Toyo Bio-Pharma(TM) (http://www.toyobiopharma.com) is a subsidiary of Toyo Shinyaku Co., Ltd., a research-driven manufacturer committed to providing consumers and clients with high-value ingredients derived from nature. With the most advanced instrumentation, continuous research and commitment to quality and integrity, Toyo Shinyaku is pioneering the use of fermentation and culturing to produce beneficial, effective products for use in the nutraceutical, functional food and cosmeceuticals industries. Toyo Shinyaku is Japan's largest developer of FOSHU (Food for Specialized Health Use) products and ODM (Original Design Manufacturer) of supplement and skin care products. Toyo Shinyaku follows rigorous standards of ISO 9001:2000 and ISO 22000:2005, and was one of the first Japanese companies to become Food and Drug Administration (FDA) Good Manufacturing Practices (GMP)-compliant for food products and dietary supplements.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc. is a global direct selling company operating in 47 markets throughout Asia, the Americas and Europe. The company markets premium-quality personal care products under the Nu Skin(R) brand, science-based nutritional supplements under the Pharmanex(R) brand, and technology-based products and services under the Big Planet(R) brand. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskinenterprises.com.


'/>"/>
SOURCE Nu Skin Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nu Skin Enterprises to Announce Second Quarter 2008 Results
2. Medline Receives Force Majeure Notice From Hong Ray Enterprises
3. Nu Skin Enterprises to Present at Oppenheimer Consumer Growth Conference
4. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant
5. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
6. Nu Skin Enterprises Announces Slate of Candidates for its Board of Directors
7. Coventina Healthcare Enterprises, Inc. is Now ReGear Life Sciences, Inc.
8. Nu Skin Enterprises Declares Quarterly Dividend of $0.11
9. Nu Skin Enterprises Reports First-Quarter 2008 Results
10. FFF Enterprises Selects A10 Networks AX Series Advanced Traffic Manager
11. CJPS Enterprises Announces a Series of Seminars on Automotive Diversification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 (HealthDay News) -- Arguments between parents may damage ... Parents in more than 200 families were asked ... the end of each day, mothers and fathers rated ... their children. On days when parents reported conflict ... children were also strained, according to the study recently ...
(Date:8/28/2014)... 28, 2014 Biotronic, a Great Point ... neurophysiology monitoring ("IONM") company, today announced the promotion of ... Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic ... CFO in 2013 and has been an integral part ... efforts and achievements since joining the company in 2010 ...
(Date:8/28/2014)... 28, 2014 Bank lending to the private ... down by 0.13% in real terms, and continuing to fall ... study by UHY, the international accountancy network. , UHY warns ... in particular, the credit crunch lingers on. , UHY says ... last year have been wiped out by inflation. Over the ...
(Date:8/28/2014)... fermentation," when yeast that should be busily converting grape ... leaving the remaining sugar to instead be consumed by ... of researchers including UC Davis yeast geneticist Linda Bisson ... Working through a prion -- an abnormally shaped ... bacteria in fermenting wine to switch yeast from sugar ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy ... groundbreaking brain cancer research projects at the Translational ... has officially received the final regulatory approval from ... enrollment for the trial can begin. , In ... Glioblastoma Trial," TGen and its clinical partners will ...
Breaking Medicine News(10 mins):Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2
... , TARRYTOWN, N.Y., Nov. 24 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009. ... The session may be accessed through the Company,s web ... An archived version of the presentation will be available after ...
... lead to persistent wheezing, study finds , TUESDAY, Nov. ... pollution and indoor endotoxin are at increased risk for ... bacteria believed to trigger an immune response in humans ... College of Medicine researchers found persistent wheezing (an early ...
... less likely to become disabled, study finds , TUESDAY, ... progression of multiple sclerosis, new research suggests. , Belgian ... symptoms between the ages of 22 and 38. , Women ... 34 percent less likely to have the disease progress to ...
... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ... in China, is proud to announce,that the company received the ... to the top 100 private technology companies in the Asia ... Technology Fast 100 list every year for various,regions, such as ...
... , TEL-AVIV, ... chemicals company, today reported,results for the third quarter and nine ... Financial Results for the Third Quarter , ... $1,347 million, up,24% as compared sequentially with $1,083 million for ...
... ... media to interact with patients and share information about his North Carolina plastic surgery ... ... surgeon Dr. Richard Cummings has joined the popular social networking site Facebook to expand ...
Cached Medicine News:Health News:Traffic, Dust Linked to Asthma in Kids 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 3Health News:Sundia MediTech Receives Red Herring Asia Top 100 Award 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 3Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 4Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 5Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 6Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 7Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 8Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 9Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 10Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 2Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 3
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , August 28, 2014 According ... Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, Printers ... Trends and Forecast, 2014 - 2020" the global radiofrequency ... in 2013 and is expected to grow at a ... an estimated value of USD 5.3 billion in 2020. ...
(Date:8/28/2014)... , Aug. 28, 2014 ... research report is available in its ... in Asia-Pacific Markets to 2020 - ... Need in Newly Diagnosed and Recurrent ... Glioblastoma Multiforme ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: